Previous 10 | Next 10 |
home / stock / pcsa / pcsa articles
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Do...
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded...
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Monday. Following the market opening Monday, the Dow...
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share c...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Friday. The Dow traded up 0.41% to 37,621.2...
Processa Pharmaceuticals Inc (NASDAQ:PCSA) shares are trading higher by 36.9% to $0.28 during Friday’s session after the company announced pl...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Do...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.35% to ...
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of ...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap doses, 5-Fluorouracil (5-FU) exp...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, ke...